Chugai Pharmaceutical Co Ltd (CHGCF)
29.75
0.00 (0.00%)
USD |
OTCM |
May 31, 16:00
Chugai Pharmaceutical Enterprise Value: 43.90B for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 31, 2024 | 43.90B |
May 30, 2024 | 43.90B |
May 29, 2024 | 43.90B |
May 28, 2024 | 43.90B |
May 24, 2024 | 43.90B |
May 23, 2024 | 43.90B |
May 22, 2024 | 43.90B |
May 21, 2024 | 43.90B |
May 20, 2024 | 43.90B |
May 17, 2024 | 43.90B |
May 16, 2024 | 43.90B |
May 15, 2024 | 43.90B |
May 14, 2024 | 43.90B |
May 13, 2024 | 48.31B |
May 10, 2024 | 48.31B |
May 09, 2024 | 48.31B |
May 08, 2024 | 48.31B |
May 07, 2024 | 48.31B |
May 06, 2024 | 48.31B |
May 03, 2024 | 48.31B |
May 02, 2024 | 48.31B |
May 01, 2024 | 48.31B |
April 30, 2024 | 48.31B |
April 29, 2024 | 48.31B |
April 26, 2024 | 48.31B |
Date | Value |
---|---|
April 25, 2024 | 48.31B |
April 24, 2024 | 48.31B |
April 23, 2024 | 49.69B |
April 22, 2024 | 49.69B |
April 19, 2024 | 49.69B |
April 18, 2024 | 49.69B |
April 17, 2024 | 49.69B |
April 16, 2024 | 49.69B |
April 15, 2024 | 49.69B |
April 12, 2024 | 49.69B |
April 11, 2024 | 59.35B |
April 10, 2024 | 59.35B |
April 09, 2024 | 59.35B |
April 08, 2024 | 59.35B |
April 05, 2024 | 59.35B |
April 04, 2024 | 59.35B |
April 03, 2024 | 59.35B |
April 02, 2024 | 59.35B |
April 01, 2024 | 59.35B |
March 31, 2024 | 59.35B |
March 28, 2024 | 59.16B |
March 27, 2024 | 59.16B |
March 26, 2024 | 59.16B |
March 25, 2024 | 59.16B |
March 22, 2024 | 59.16B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
32.91B
Minimum
Jun 03 2019
85.18B
Maximum
Jul 06 2020
49.54B
Average
48.04B
Median
Mar 09 2022
Enterprise Value Benchmarks
Takeda Pharmaceutical Co Ltd | 70.78B |
Nxera Pharma Co Ltd | 932.97M |
PeptiDream Inc | 1.615B |
Healios KK | 57.40M |
Enterprise Value Related Metrics
Net Income (Quarterly) | 501.30M |
Revenue (Quarterly) | 1.597B |
Total Expenses (Quarterly) | 923.59M |
EPS Diluted (Quarterly) | 0.3046 |
Gross Profit Margin (Quarterly) | 69.21% |
Profit Margin (Quarterly) | 31.40% |
Earnings Yield | 4.62% |
Operating Earnings Yield | 6.24% |
Normalized Earnings Yield | 4.621 |